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ABSTRACT
Introduction: To evaluate the effects of a new
lubricating, antioxidant solution (VisuEvo) on
dry eye disease (DED) in patients undergoing
cataract surgery.
Methods: Patients requiring cataract surgery
with either healthy ocular surface or mild DED
(tear break-up time, TBUT[ 7, Schirmer I test
[15 mm/5 min) were enrolled in this multi-
center, open-label, randomized, prospective
study. Scheduled visits were 2 weeks before
surgery (screening), day of surgery (V0), week 1
(V1), and 2 (V2) after surgery. VisuEvo was self-
administered three times daily for the whole
study duration (group A); the control group
(group B) had no tear substitute administration.
The primary endpoint was the change in TBUT
over time; the secondary endpoints were chan-
ges in Ocular Surface Disease Index (OSDI),
ocular surface staining, the Schirmer I test, and
osmometry.
Results: A total of 45 patients were included
(group A, 23; group B, 22; age 74 ± 8 years). At
the screening, TBUT was similar between the
groups (group A, 8.5 ± 1.8 s; group B, 7.8 ± 0.7,
p = 0.11). At the scheduled visits, TBUT increase
vs screening visit was significantly higher in
group A: ?1.2 s at V0, ?1.4 s at V1, and ?1.9 s at
V2 (p\0.01). Also, OSDI was significantly
lower in group A at V0, V1, and V2 (p\0.027).
After surgery, corneal staining was absent in
65–78% of group A compared with 54–59% in
group B. The two groups did not show any sig-
nificant differences of osmometry and the
Schirmer I test.
Conclusions: The ocular surface was more pro-
tected and quickly restored from surgery when
VisuEvo was used from 2 weeks preoperatively
to 2 weeks postoperatively.
Trial registration: ClinicalTrials.gov identifier,
NCT03833908
Keywords: Cataract surgery; Dry eye disease;
Lubricating eye drops; Ocular surface;
Ophthalmology
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.11920959.
P. Fogagnolo (&)  D. Marchina  C. Quisisana 
L. Rossetti
Eye Clinic, ASST Santi Paolo Carlo, San Paolo
Hospital, Milan, Italy
e-mail: paolo.fogagnolo@unimi.it
P. Fogagnolo  D. Marchina  C. Quisisana 
L. Rossetti
Department of Health Sciences, University of Milan,
Milan, Italy
E. Favuzza  M. Cennamo  R. Vignapiano 
R. Mencucci
Department of Oto-Neuro-Ophthalmological
Surgical Sciences Eye Clinic, University of Florence,
Florence, Italy
Adv Ther (2020) 37:1664–1674
https://doi.org/10.1007/s12325-020-01288-z
Key Summary Points
Why carry out this study?
An adequate ocular surface preparation is
needed in patients scheduled for cataract
surgery, both in individuals with ocular
surface disease and a healthy ocular
surface. This practice is poorly adopted.
Cataract surgery often induces or
exacerbates DED, especially in the elderly.
What was learned from the study?
The use of a prophylactic lubricating
treatment 2 weeks before scheduled
cataract surgery, and continued 2 weeks
postoperatively, protected patients from
iatrogenic DED.
The preoperative administration of the
new ophthalmic solution, VisuEvo,
guaranteed optimal ocular surface health
until the day of surgery and preserved
patients from the natural course of DED
postoperatively.
INTRODUCTION
Cataract is a leading cause of visual impairment
in all regions of the world [1], and surgery is the
only treatment choice for visually disabling
cataracts [2]. Regardless of the surgical tech-
nique employed (e.g., phacoemulsification,
manual small-incision cataract surgery, or
extracapsular cataract extraction), cataract sur-
gery has been shown to induce or exacerbate
dry eye disease (DED) [3]. In most cases, DED is
transient after surgery. Dry eye symptoms may
occur at variable periods after uncomplicated
phacoemulsification, combined with a decrease
in tear break-up time (TBUT) and an increase in
ocular surface staining [4–6]. Also, cataract sur-
gery may trigger an entry in a vicious cycle of
chronic DED, which occurs with a prevalence of
about 10% [5].
The pathophysiological mechanisms under-
lying cataract surgery-induced DED are multi-
factorial and include the use of preoperative
prophylactic medications, topical anesthetics
and antiseptics, exposure desiccation, possible
light toxicity from the operating microscope,
corneal nerve transection, increase of inflam-
matory factors, goblet cell loss, and meibomian
gland dysfunction [6–9]. The surgical trauma
related to cataract surgery is associated with the
production of oxygen-free radicals, proteolytic
enzymes, prostaglandins, leukotrienes and
inflammatory cytokines, which may affect cor-
neal sensitivity, increase inflammation and
contribute to tear film instability [7]. Of note,
conjunctival goblet cell density decreased
remarkably following uncomplicated cataract
surgery and did not return to baseline even
3 months postoperatively [3].
A healthy ocular surface is crucial to achiev-
ing the best outcome in cataract surgery. Ocular
surface preparation is crucial in patients with
established ocular surface disease, and it is also
helpful in those with minimal signs or symp-
toms of the surface disease. As the incidence
and severity of DED may increase after cataract
surgery [4], an assertive approach in the man-
agement of ocular surface disease since the pre-
operative phases is recommendable in the
majority of patients. However, there is a dis-
crepancy between the high number of com-
mercially available lubricating eyedrops and the
low number of studies exploring their clinical
usefulness. Only scarce evidence is currently
available on the efficacy of these types of eye
drops in reducing DED after cataract surgery.
This study reports on the potential clinical
benefits of a new approach to cataract surgery-
associated DED based on the administration of
an innovative preservative-free, antioxidant
activity ophthalmic solution (VisuEvo) pre-
operatively and some weeks after surgery.
METHODS
This was a multicenter, pre-marketing, open-
label, randomized, prospective study. From
November 29, 2018 to June 17, 2019, consecu-
tive patients scheduled to receive cataract
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surgery with normal ocular surface or mild DED
(including subclinical DED) were enrolled at the
Eye Clinic of Careggi Hospital, University of
Florence, Italy, and at San Paolo Hospital—SST
Santi Paolo e Carlo of Milan, University of
Milan, Italy. Informed consent was obtained
from all participants, and the study was
reviewed and approved by the Ethics Commit-
tees of two Institutions (Comitato Etico Area
Vasta Centro, Comitato Etico Milano Area 1).
The study was conducted in accordance with
this approval and national regulations, and
adhered to the tenets of the Declaration of
Helsinki as revised in 2013. The trial was regis-
tered at https://www.clinicaltrial.gov (identifier:
NCT03833908).
The study design included four visits:
2 weeks before the planned cataract surgery
(screening visit), day of cataract surgery (base-
line visit), and then at weeks 1 and 2 after sur-
gery (post-surgery visits 1 and 2, respectively).
Patients were enrolled in the study at the
screening visit, and randomized with a 1:1 ratio
(by means of a list of random numbers) to one
of two groups each of 23 patients: group A (in-
vestigational group), treated with VisuEvo
administered three times daily starting 2 weeks
before surgery until 2 weeks post-surgery for a
total of 4 weeks; and group B (comparator
group), without any tear substitute
administration.
Three days before surgery, the patients of
both groups received standard treatment with
ofloxacin. Soon after surgery, they had a stan-
dard postoperative treatment (topical dexam-
ethasone for 10 days associated with ofloxacin
for 7 days). Patients were allowed to continue
any systemic or local medications for their
concomitant diseases. Before the screening visit
for all patients, no topical ophthalmic medica-
tion, including lubricating eye drops, were
administered for at least 4 days. Major inclusion
criteria encompassed adults of both genders
diagnosed with cataract requiring surgery, with
healthy ocular surface or mild DED (including
subclinical DED) with TBUT[ 7, and Schirmer
test [15 mm/5 min. Subjects were excluded
from enrollment if they carried neuropathic
DED (e.g., diabetes, long-standing contact lens
wearing, previous ocular herpes infections,
previous eye surgery), proven or suspected
glaucoma or ocular hypertension, Sjo¨gren syn-
drome and/or other autoimmune diseases,
complicated cataract, corneal diseases, surface
eyes disturbances (e.g., past or active cicatricial
conjunctivitis, ocular surface burns, corneal
trauma), keratinization of the eyelid margin
and/or other functional and anatomic eyelid
abnormalities.
The primary objective of the study was to
compare the change over time in TBUT between
the two treatment groups. The secondary
objectives were the performance of VisuEvo in
reducing changes in ocular surface staining
(according to a modified Oxford Scale consid-
ering also the staining of the surgical incisions)
[10], eye disability determined by the Ocular
Surface Disease Index questionnaire (OSDI;
1995, Allergan, Irvine, CA, US) [11], Schirmer I
test, and osmometry. The equipment used for
assessing the clinical variables was the slit lamp
ophthalmoscopy, the tear film osmometer, the
fluorescein strips, and the Schirmer test strips
without anesthesia.
The safety profile was assessed by monitoring
the occurrence of adverse events (AEs).
Patients were asked to self-administer study
medications during the study. VisuEvo is an
ophthalmic solution with antioxidant activity
(scavenger of oxygen free radicals) that uses an
innovative liposomal nanodispersion associated
with vegetable oil rich in omega 3 (docosahex-
aenoic acid and eicosapentaenoic acid), vitamin
D and vitamin A palmitate. VisuEvo is a 10-ml,
preservative-free, multidose bottle provided
with a dispenser capable of delivering the drops
in sterile conditions and preserving the content
from exogenous contamination during use
(Novelia System). The structure of the oph-
thalmic solution is thought to be effective in
most forms of DED apart from Sjo¨gren disease,
with a significant hyperevaporative component.
All patients received cataract surgery
according to standard operating procedures:
pupil dilation with three drops of Visumidriatic
Tropicamide (Visufarma, Italy) and Visum-
idriatic Phenilephrine (Visufarma), prepara-
tions with three drops of single-dose
oxybuprocaine (Novesina 4 mg/ml; Labora-
toires Thea, France), 10% iodine solution for
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15 min on the eyelid skin and 5% iodine solu-
tion (Oftasteril; Alfa Intes, Italy) for 5 min on
the conjunctival sac. Standard phacoemulsifi-
cation with clear cornea temporal incision was
performed.
In this study, no intraoperative and postop-
erative complications occurred.
A sample size of 42 patients was estimated to
provide 80% power to detect a significant dif-
ference between treatment arms by a two-sided
t test for unpaired data (type I error set to 0.05).
A 2-s change in TBUT has been considered as
clinically relevant and, based on previous stud-
ies [13–15], 2.2 s has been assumed as the stan-
dard deviation. Planning to randomize a total of
46 patients (23 in each treatment arm) allowed
for a 5% drop-out rate (sample size estimation
was performed using SAS software v.9.4). In the
study analysis, the following populations were
considered: Intent-to-Treat (ITT) set, consisting
of all randomized patients; and Safety Analysis
(SA) set, consisting of all randomized patients,
according to their actual treatment.
RESULTS
Forty-six subjects were enrolled; 45 patients
completed the study, 23 in group A and 22 in
group B. One subject withdrew their informed
consent between screening and the baseline
visit. This patient was excluded from the anal-
ysis because they did not provide post-baseline
data. The two groups were well matched for
gender, ethnicity, age, height, weight, and the
time elapsed from cataract diagnosis, and no
statistically significant differences were
observed. The demographic results are described
in Table 1.
The results of the study are summarized in
Table 2. At the screening visit, the TBUT values
were similar in group A and in group B
(8.5 ± 1.8 and 7.8 ± 0.7 s, respectively,
p = 0.11). At baseline before the cataract surgery
(visit 0), the mean TBUT value in group A was
comparable to the one at the screening visit,
while a decrease of 0.6 s was observed in group
B. The difference between the two groups was
statistically significant (p = 0.01) (Fig. 1). One
week after surgery (visit 1), TBUT decreased in
the group A (7.4 ± 1.5 s) compared to previous
visits, whereas it decreased in the group B to
6.0 ± 1.3 s (p = 0.002). At visit 1, TBUT values
were worse than at the screening visit in 57% of
patients in group A and 91% in group B. Two
weeks after surgery (visit 2), TBUT showed a
trend toward the initial mean value observed at
the screening visit in group A, while it further
decreased in group B (p = 0.0002). The differ-
ence between the two groups further increased
compared to the visit 1 (Fig. 1). Comparing the
beginning and the end of the study, TBUT
worsened in 57% of patients in group A, and
Table 1 Demographic results (ITT population)
Group A
(n = 23)
Group B
(n = 22)
Total
(n = 45)
Gender n (%)
Male 7 (30.4%) 8 (36.4%) 15 (33.3%)
Female 16 (69.6%) 14 (63.6%) 30 (66.7%)
Ethnic group
Caucasian 23 22 45
Age (years)
Mean ± SD 73 ± 7 76 ± 8 74 ± 8
Median
(range)
72 (52–88) 77 (54–86) 76 (52–88)
Height (cm)
Mean ± SD 163 ± 10 163 ± 8 163 ± 9
Median
(range)
164
(146–180)
160
(140–175)
162
(140–180)
Weight (kg)
Mean ± SD 69 ± 16 71 ± 13 70 ± 14
Median
(range)
68 (45–95) 68 (45–100) 68 (45–100)
Time elapsed from cataract diagnosis (days)a
Mean ± SD 600 ± 291 763 ± 321 679 ± 314
Median 732 765 740
a Time elapsed from cataract diagnosis was calculated as
(Cataract diagnosis date—Visit - 1 date) ? 1
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82% in group B (Table 3). Stratifying the
patients into four classes according to the
severity of TBUT (e.g.,\5 s, 5–7 s, 8–9 s, C 10 s),
at the screening, there were similar distributions
in the two groups. However, during the fol-
lowing visits, a progressive advantage of group
A over group B emerged (Table 4).
At the screening visit, OSDI scores were
similar in both groups. OSDI overall decreased
the day of the surgery; the reduction was sig-
nificantly higher in group A compared with
group B (p = 0.01). During the two post-surgery
visits, a small increase of OSDI score was found
in group A;, while the increase was greater in
the unprotected group B (Fig. 2). The differences
in mean OSDI scores between the groups were
statistically significant at both visits 1 and 2
(p = 0.01 and p = 0.027, respectively).
After surgery, fluorescein staining showed a
much higher proportion of patients with opti-
mal ocular surface protection in the group
treated with VisuEvo (group A) compared to
group B (Table 2). A greater percentage of
patients (78 and 65% at visits 1 and 2, respec-
tively) had grade 0 in group A versus those in
group B (59 and 54%, respectively). Also, a
minor proportion of patients had a staining
grade 2 in group A at both visits (4.3%) versus
those in group B (18 and 23%, respectively)
(Fig. 3).
Osmometry was similar in the two groups at
screening, and no statistically significant dif-
ference was observed between the groups at any
visit (Table 2). Also, the mean values of the
Schirmer I test were similar between groups
throughout the study, and no statistical signif-
icance between groups at any visit was detected
(Table 2).
During the study, three patients (6.7%) in
group A reported four ocular AEs: iris incarcer-
ation in the corneal wound, iridocyclitis,
increased eye pressure after surgery, and con-
junctivitis. No AE met the criteria for being
classified as severe or serious. Only the patient
experiencing increased eye pressure after sur-
gery reported the AE to be of moderate
intensity.
Table 2 Primary and secondary efficacy variables at each
study visit (ITT population)
Variables at
study visits
Group A
(n = 23)
Group B
(n = 22)
p value
TBUT—mean ± SD
Visit - 1 8.5 ± 1.8 7.8 ± 0.7 0.11
Visit 0 8.4 ± 1.8 7.2 ± 0.9 0.01
Visit 1 7.4 ± 1.5 6.0 ± 1.3 0.002
Visit 2 7.9 ± 1.6 6.0 ± 1.5 0.0002
OSDI Questionnaire Score—mean ± SD
Visit - 1 13 ± 8 14 ± 8 0.55
Visit 0 6 ± 5 11 ± 7 0.01
Visit 1 8 ± 7 16 ± 12 0.014
Visit 2 9 ± 8 16 ± 11 0.027
Osmolimetry test—mean ± SD
Visit - 1 305 ± 17 303 ± 13 0.77
Visit 0 306 ± 17 299 ± 17 0.21
Visit 1 302 ± 18 304 ± 17 0.79
Visit 2 304 ± 16 302 ± 13 0.66
Schirmer I test—mean ± SD
Visit - 1 20 ± 6 18 ± 5 0.31
Visit 0 20 ± 7 16 ± 5 0.08
Visit 1 16 ± 6 16 ± 8 0.84
Visit 2 18 ± 8 16 ± 7 0.52
Staining grade with fluorescein—n (%)
Visit 1
0 18 (78.3%) 13 (59.1%)
1 4 (17.4%) 5 (22.7%)
2 1 (4.3%) 4 (18.2%)
Visit 2
0 15 (65.2%) 12 (54.5%)
1 7 (30.4%) 5 (22.7%)
2 1 (4.3%) 5 (22.7%)
Visit - 1 screening; Visit 0 baseline; Visit 1 week 1; Visit
2 week 2
1668 Adv Ther (2020) 37:1664–1674
DISCUSSION
Two of the most relevant risk factors for DED
are anterior segment surgery [3, 16, 17] and
increased age [3]. As cataract surgery is com-
monly performed on the elderly, DED fre-
quently occurs after this procedure.
Approximately one-third of individuals experi-
ence mild or greater DED symptoms after sur-
gery [18]. Of note, the DED prevalence may be
different depending on the diagnostic criteria. A
recent report by DEWS recommends non-inva-
sive diagnostic tests [19]. Nevertheless, TBUT,
together with the OSDI scores and Schirmer I
test, is still the most commonly used parameter
to ascertain the presence of DED and monitor
its changes over time [20, 21]. Our study pop-
ulation undergoing cataract surgery had similar
features to that of previous studies [20, 21]. Of
the whole study population, individuals with
normal ocular surfaces (TBUT[ 7 s) and no
relevant DED symptoms (OSDI B 12) were just
38% at baseline.
In our study, patients in the comparator
group showed the natural course of DED after
surgery. These patients had a detriment of TBUT
at the moment of surgery, possibly due to pre-
surgery preparation with antibiotics, which are
Fig. 1 Trend of TBUT (s) among study visits by study treatment group
Table 3 Number and proportion of patients improved, stablilized and worsened in TBUT values during study visits
compared to screening visit (visit - 1) by treatment group (ITT population)
Group A
n (%)
Group B
n (%)
Improved Stabilized Worsened Improved Stabilized Worsened
Visit - 1 vs Visit 0 5 (22) 8 (35) 10 (43) 3 (14) 10 (45) 9 (41)
Visit - 1 vs Visit 1 2 (9) 8 (35) 13 (57) 0 (0) 2 (9) 20 (91)
Visit - 1 vs Visit 2 6 (26) 4 (17) 13 (57) 1 (5) 3 (14) 18 (82)
Improved difference between two TBUT values[ 0; Stabilized difference between two TBUT values = 0; Worsened
difference between two TBUT values\ 0
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known to be toxic to the ocular surface [22, 23].
In these patients, cataract surgery was associ-
ated with further worsening of the ocular sur-
face health (TBUT, staining), and the effect was
clear after 1 week, without signs of improve-
ment at the 2-week visit.
Conversely, patients receiving the oph-
thalmic solution VisuEvo were more protected
from iatrogenic DED. This ophthalmic solution
was able to fully counteract the toxic effects of
eye drops used to prepare patients for surgery,
so that they received surgery with overall nor-
mal homeostasis of the ocular surface (as TBUT
was similar to baseline). Surgery also worsened
the ocular surface on these patients, but the
effect was significantly lower than in group B
(Fig. 1). The TBUT differences between the two
groups progressively increased during the study
up to the last visit, when it was the largest.
TBUT findings were parallel to the trend of
OSDI score, showing a greater reduction of
ocular disability compared to patients unpro-
tected with the ophthalmic solution. The use of
VisuEvo was also associated with a larger per-
centage of subjects with no corneal staining at
fluorescein after surgery (65–78% in group A vs.
54–59% in group B; Fig. 3).
The results of the current study are consis-
tent with previous reports, which have shown
that cataract surgery can lead to worsened all
dry eye test values regardless of a previous DED
[3]. To assess the efficacy of the new ophthalmic
solution in protecting against the ocular surface
damages, we used conventional dry eye tests. In
our study, the TBUT, OSDI score and Oxford
ocular surface staining system agreed in esti-
mating DED occurrence and severity [5], while
Schirmer I and osmometry did not contribute in
evaluating our study population. The low per-
formance of Schirmer I was expected given the
normal function of the main lacrimal gland at
baseline. Also, osmometry did not show any
statistical difference in the two groups during
the study, with negligible changes after surgery
and in the group treated with VisuEvo. The
limited relevance of osmometry in this study
may be the consequence of several factors. On
the basis of inclusion and exclusion criteria, the
study population had no inflammatory condi-
tions affecting the ocular surface before surgery;T
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also, a high percentage of subjects had no DED
before the study (see mean TBUT at visit - 1,
Table 1). For these reasons, mean osmometry at
visit - 1 was normal as expected, which made a
further amelioration of the test unlikely.
Moreover, the postoperative use of steroids may
have ameliorated the conditions of the ocular
surface, thus stabilizing osmometry, both miti-
gating the negative effects of surgery and, in the
treated group, the positive effects of VisuEvo.
Fig. 3 Distribution of patients assessed by staining grade with fluorescein by study group at Visit 1 and Visit 2 post-surgery
Fig. 2 Trend of OSDI Questionnaire Score among study visits by study treatment group
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Many studieshave shown the effects of various
tear film substitutes [12, 24–26, 28–30] and
cyclosporine [27] in ameliorating iatrogenicDED.
Still, as correctly stated by a recent report and
despite the recent recommendationsbyDEWS[3],
‘‘there are no prophylactic medications com-
monly used to prevent the development of post-
operative dry eye’’ [9]. In our opinion, the main
value of the present study is to raise attention to
the possible prevention of the iatrogenic DED
effects by prophylactic lubricating treatment. To
the best of our knowledge, this prevention is a
poorly explored topic. In our study, the protective
treatmentwitha lubricating agent started2 weeks
before cataract surgery. This prophylaxis was
associated with better homeostasis of the ocular
surface on the day of surgery compared to the
control group. Such a positive milieu may have
prevented or reduced the anterior segment
inflammation, leading to postoperative protec-
tion toward DED signs and symptoms. Of note,
the differences between the two groupsmay have
been even higher, considering that group A
encompassed the patients (n = 3) with AEs.
Although these AEs were unrelated to study
treatment, they temporarily worsened the post-
operative course of these patients.
Our study has some limitations. We did not
assess a possible full recovery of ocular surface
health due to the lack of a long-term follow-up
(2–3 months) after surgery like other trials [4, 5].
However, as well as other authors [5], we have
detected the peak of the severity of dry eye
conditions in both groups at the 7-day visit
post-surgery, and the values of TBUT test and
OSDI scores confirm this trend. The lack of a
long-term follow-up visit prevented us from
evaluating the return to normality of the
patients of the control group and estimating a
possible shorter recovery time for patients pro-
tected with the innovative lubricating agent.
Also, we included in the study only subjects
with TBUT[7 s. Future studies may be focused
on the performances of the ophthalmic solu-
tion VisuEvo to prevent the worsening of pre-
existing DED in different groups of patients,
such as those with moderate-to-severe DED or
other comorbidities (e.g., high evaporation,
blepharitis, glaucoma, corneal neuropathy).
Also, it may be interesting to compare VisuEvo
with other tear film substitutes both in iatro-
genic and non-iatrogenic DED scenarios.
CONCLUSIONS
The application of a 2-week preoperative treat-
ment with an innovative lipid tear film substi-
tute (VisuEvo) administered twice-daily
significantly reduced postoperative DED-related
signs and symptoms to almost normal values in
elderly subjects undergoing cataract surgery.
The clinical value is even more evident by
comparing the treated group with subjects
receiving standard preparation and postopera-
tive care. The decline of the ocular surface
health of the patients in the control group
retraced the natural prognosis due to the
underestimated postoperative DED.
Further studies will confirm the long-term
VisuEvo efficacy in the complete recovery
from postoperative DED damages induced by
cataract surgery and explore its potential in the
presence of more severe DED.
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